Flexi
Flexion Therapeutics (FLXN) got here out with a quarterly lack of $0.88 per share versus the Zacks Consensus Estimate of a lack of $1.01. This compares to lack of $1.07 per share a yr in the past. These figures are adjusted for non-recurring gadgets.
This quarterly report represents an earnings shock of 12.87%. 1 / 4 in the past, it was anticipated that this specialty pharmaceutical firms that focuses on ache aid would publish a lack of $1.01 per share when it really produced a lack of $1, delivering a shock of 0.99%.
During the last 4 quarters, the corporate has surpassed consensus EPS estimates 4 instances.
Flexion Therapeutics, which belongs to the Zacks Medical – Medicine trade, posted revenues of $23.65 million for the quarter ended December 2019, surpassing the Zacks Consensus Estimate by 0.65%. This compares to year-ago revenues of $9.54 million. The corporate has topped consensus income estimates thrice over the past 4 quarters.
…